Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles

Zhao, Kai; Shi, Xingming; Zhao, Yan; Wei, Haixia; Sun, Qingshen; Huang, Tingting; Zhang, Xiaoyan; Wang, Yunfeng

doi:10.1016/j.vaccine.2011.09.029

Cited by 85 publications

(54 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Similar efficiencies have been reported by other investigators who used the complex coacervation technique for encapsulation. 21,32,36,38 The release profiles of encapsulated DMOMP from chitosan nanoparticles were pH dependent as revealed by the results obtained in SGF (pH 2), SIF (pH 7) and PBS (pH 7). Release profile of any biomaterial from a nanoparticle is an important attribute in nanovaccine development as it can influence the immunological response and immunization protocol.…”

Section: Transfection Studies: Gene Delivery and Protein Expression Smentioning

confidence: 93%

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Cambridge¹,

Singh²,

Waffo³

et al. 2013

IJN

View full text Add to dashboard Cite

Chlamydia trachomatis is a bacterial sexually transmitted infection affecting millions of people worldwide. Previous vaccination attempts have employed the recombinant major outer membrane protein (MOMP) of C. trachomatis nonetheless, with limited success, perhaps, due to stability, degradation, and delivery issues. In this study we cloned C. trachomatis recombinant MOMP DNA (DMOMP) and encapsulated it in chitosan nanoparticles (DMCNP) using the complex coacervation technique. Physiochemical characterizations of DMCNP included transmission and scanning electron microcopy, Fourier transform infrared and ultravioletvisible spectroscopy, and zeta potential. Encapsulated DMOMP was 167-250 nm, with a uniform spherical shape and homogenous morphology, and an encapsulation efficiency . 90%. A slow release pattern of encapsulated DMOMP, especially in acidic solution, was observed over 7 days. The zeta potential of DMCNP was ∼8.80 mV, which indicated that it was highly stable. Toxicity studies of DMCNP (25-400 µg/mL) to Cos-7 cells using the MTT assay revealed minimal toxicity over 24-72 hours with .90% viable cells. Ultra-violet visible (UV-vis) spectra indicated encapsulated DMOMP protection by chitosan, whereas agarose gel electrophoresis verified its protection from enzymatic degradation. Expression of MOMP protein in DMCNPtransfected Cos-7 cells was demonstrated via Western blotting and immunofluorescence microscopy. Significantly, intramuscular injection of BALB/c mice with DMCNP confirmed the delivery of encapsulated DMOMP, and expression of the MOMP gene transcript in thigh muscles and spleens. Our data show that encapsulation of DMOMP in biodegradable chitosan nanoparticles imparts stability and protection from enzymatic digestion, and enhances delivery and expression of DMOMP in vitro and in mice. Further investigations of the nanoencapsulated DMCNP vaccine formulation against C. trachomatis in mice are warranted.

show abstract

Section: Transfection Studies: Gene Delivery and Protein Expression Smentioning

confidence: 93%

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Cambridge¹,

Singh²,

Waffo³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…The in vitro and in vivo cytotoxicity of the pFDNA-CS/PLGA-NPs were evaluated as previously described. 36 Chickens in one group were immunized, by IN route, with 0.2 mL of the pFDNA-CS/PLGA-NPs, which contained a total of 200 μg of plasmid DNA. Chickens in the other group were immunized, by IM route, with 0.2 mL of the naked plasmid DNA.…”

Section: The Safety Of Pfdna-cs/plga-npsmentioning

confidence: 99%

“…Chitosan-coated PLGA nanoparticles as an efficient delivery system periodically collected (after 0, 6,12,24,36,48,72,96,120,144,168,192,216, and 240 hours) and centrifuged at 10,000 r/min for 10 minutes at 4°C. The collected pFDNA-CS/ PLGA-NPs were counted.…”

mentioning

confidence: 99%

“…Western blot analysis was carried out as previously described. 36 Briefly, after 72 hours of transfection, the 293T cells were collected and disrupted using radioimmunoprecipitation assay solution (50 mmol/L Tris-HCl [pH 8.5], 5 mmol/L 2-hydroxy-1-ethanethiol, 100 mmo1/L KCl, 1 mmol/L phenylmethanesulfonyl fluoride, and 1% Nonidet P-40 (octylphenoxypolyethoxyethanol). The lysate was centrifuged at 14,000 r/min at 4°C, and the supernatant was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine

Zhao¹,

Zhang²,

Zhang³

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

We determined the efficacy and safety of chitosan (CS)-coated poly(lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) as a delivery system for a vaccine to protect chickens against Newcastle disease virus (NDV). The newly constructed vaccine contained DNA (the F gene) of NDV. The Newcastle disease virus (NDV) F gene deoxyribonucleic acid (DNA) plasmid (pFDNA)-CS/PLGA-NPs were spherical (diameter =699.1±5.21 nm [mean ± standard deviation]) and smooth, with an encapsulation efficiency of 98.1% and a Zeta potential of +6.35 mV. An in vitro release assay indicated that CS controlled the burst release of plasmid DNA, such that up to 67.4% of the entire quantity of plasmid DNA was steadily released from the pFDNA-CS/PLGA-NPs. An in vitro expression assay indicated that the expression of nanoparticles (NPs) was maintained in the NPs. In an immunization test with specific pathogen-free chickens, the pFDNA-CS/PLGA-NPs induced stronger cellular, humoral, and mucosal immune responses than the plasmid DNA vaccine alone. The pFDNA-CS/PLGA-NPs did not harm 293T cells in an in vitro assay and did not harm chickens in an in vivo assay. Overall, the results indicated that CS-coated PLGA NPs can serve as an efficient and safe mucosal immune delivery system for NDV DNA vaccine.

show abstract

“…14 Its poor immunogenicity and insecurity due to incomplete inactivation limitations the application of inactivated vaccines. 15 In recent years, scores of people pay close attention to DNA vaccines as an emerging vaccines, 16 which can induce perfect mucosal, and humoral immune responses. 17,18 …”

Section: Newcastle Disease Virus Vaccinementioning

confidence: 99%

Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine

Sun¹,

Zhang

Shi

et al. 2014

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

A n overwhelming number of medicines on the market are oral medicine with the disadvantage of lower bioavailability universally. Newcastle disease (ND) has become a serious disease that threatens the poultry industries in many countries, and there are no treatments available for ND. The biodegradable materials could be surface modified and protect antigen or DNA from damage. Furthermore, nanoparticles are also a potential drug delivery with proper size. However, Newcastle disease virus (NDV) vaccines encapsulated in nanoparticles were widely used due to their proved a high safety and induced quicker and better mucosal and humoral immune responses. Here we review the results of mucosal immune delivery system for ND. Due to the safety, low toxicity, and better immunogenicity of the mucosal immune delivery system, our studies provide a clearly view that used the biodegradable materials to research and develop the human vaccines to save more patients' lives. These promising results provide a foundation for testing the approach in humans.

show abstract

Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles

Cited by 85 publications

References 35 publications

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles

Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine

Newcastle disease virus vaccine encapsulated in biodegradable nanoparticles for mucosal delivery of a human vaccine

Contact Info

Product

Resources

About